Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1 1

Status

Completed 59Terminated 20Active not recruiting 16Recruiting 13Unknown 6Withdrawn 5Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 3OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 4Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 28Carcinoma, Non-Small-Cell Lung 20Triple Negative Breast Neoplasms 9Ovarian Neoplasms 8Lung Neoplasms 8Uterine Cervical Neoplasms 6Adenocarcinoma of Lung 6Neoplasms 5Neoplasm Metastasis 5Esophageal Neoplasms 5Carcinoma, Ovarian Epithelial 4Stomach Neoplasms 3Recurrence 3Prostatic Neoplasms 3Esophageal Squamous Cell Carcinoma 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Platinum-Refractory Fallopian Tube Carcinoma 2Pancreatic Neoplasms 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Adenocarcinoma, Bronchiolo-Alveolar 2Unspecified Adult Solid Tumor, Protocol Specific 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrent High Grade Uterine Cancer 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

Radiosurgery 7Oxaliplatin 7Docetaxel 7Paclitaxel 5Fluorouracil 5Nivolumab 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Carboplatin 4Capecitabine 4Trastuzumab 3Radiotherapy 3Radiation 3Leucovorin 3Erlotinib Hydrochloride 3Cyclophosphamide 3Cetuximab 3Bevacizumab 3spartalizumab 2sipuleucel-T 2repotrectinib 2pembrolizumab 2pazopanib 2orteronel 2fludarabine 2atezolizumab 2aldesleukin 2Temozolomide 2Surveys and Questionnaires 2Sunitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × Neoplasm Metastasis × Paclitaxel × Clear all
NCT03841747 2024-03-12

PELICAN

Queen Mary University of London

Phase 2 Withdrawn
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04602117 2023-11-18

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

QuantumLeap Healthcare Collaborative

Phase 1 Withdrawn
BreastGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02929576 2018-10-22

ENDEAR

Pfizer

Phase 3 Withdrawn
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02274012 2017-03-14

Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment

Columbia University

Phase 2 Withdrawn
Gastrointestinal

Esophageal Neoplasms, Neoplasm Metastasis

NCT01169870 2012-01-04

Genexol-PM Versus Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients

National Cancer Center, Korea

Phase 2 Withdrawn
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡